BTK protein and phospho-BTK levels did not correlate with age (Supplemental Figure 1) or clinical parameters, such as disease duration, time to and between the first and second attack, MRI activity, and time to conversion to secondary progression (data not shown) in these MS subgroups. This evidence concerns the gene BTK and myeloid sarcoma.